This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Preparations

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There are several types of insulin preparation:

  • very rapidly-acting insulin
  • short-acting
  • medium-acting and long-acting insulin
  • insulin mixes

Inhaled insulin (1):

  • is available as a rapid acting insulin; studies in people with type 1 diabetes suggest rapid pharmacokinetics
  • pilot study found evidence that compared with injectable rapid-acting insulin, supplemental doses of inhaled insulin taken based on postprandial glucose levels may improve blood glucose management without additional hypoglycemia or weight gain (1)
    • although results from a larger study are needed for confirmation

  • Exubera, an inhaled form of rapid acting insulin developed by Pfizer, became the first inhaled insulin product to be marketed in 2006 (2)
    • but poor sales led Pfizer to withdraw it in 2007
    • Afrezza developed by Mannkind, that uses a different technology (technosphere) was approved by the FDA in 2014
      • technosphere technology (2):
        • contains recombinant human insulin dissolved with powder (fumaryl diketopiperazine)
        • once inhaled, technosphere insulin is rapidly absorbed upon contact with lung surface
        • inhalable insulin is delivered with a thumb size inhaler with a rather increased dosing flexibility
        • both components, insulin and powder (fumaryl diketopiperazine) are almost completely cleared from the lungs of healthy individuals within 12 hours of inhalation. In contrast to Exubera (8-9%) only 0.3% of insulin of inhaled insulin remained in lungs after 12 hours
      • FDA approved Afrezza with a caution (Risk Evaluation and Mitigation Strategy) for a communication plan to inform health care professionals about the serious risk of acute bronchospasm associated with Afrezza

Reference:

  • ADA. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2021. Diabetes Care 2021;44(Suppl. 1):S111-S124
  • Mohanty RR, Das S. Inhaled Insulin - Current Direction of Insulin Research. J Clin Diagn Res. 2017;11(4):OE01-OE02. doi:10.7860/JCDR/2017/23626.9732

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.